Literature DB >> 21707478

Structural basis for therapeutic intervention of uPA/uPAR system.

Jacky Chi Ki Ngo1, Longguang Jiang, Zhonghui Lin, Cai Yuan, Zhuo Chen, Xu Zhang, Haiyang Yu, Jundong Wang, Lin Lin, Mingdong Huang.   

Abstract

Urokinase-type plasminogen activator (uPA) is one of the two physiological serine proteases responsible for the activation of plasminongen to plasmin. uPA activity is regulated by its inhibitors (PAI-1 and PAI-2) and its receptor (uPAR), and an expanding list of their interacting proteins. In addition to plasminogen activation, this system also plays important roles in the regulation of many cellular processes including cell proliferation, adhesion and migration. It is beyond reasonable doubt that this enzyme system plays a central role in tumor biology and represents a high potential target for therapeutic intervention of tumor growth and metastasis. During the past fifteen years, crystal structures of uPA and its inhibitors have facilitated the development of uPA inhibitors. Many crystal structures of proteins in the uPA/uPAR system have also been reported recently, especially a series of structures of uPAR and its complexes with vitronectin and uPA, facilitating the development and evaluation of uPAR inhibitors. Recent progress on uPA inhibitors will be summarized in this article. The unique structural features and the druggable potentials of these new structures will also be discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21707478     DOI: 10.2174/138945011797635911

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  15 in total

1.  Effect of lentivirus-mediated uPA silencing on the proliferation and apoptosis of chondrocytes and the expression of MMPs.

Authors:  Chen-Hui Shi; Wei-Shan Wang; Zhen-Dong Zhang; Chang-Jun Li; Feng-Jing Guo; Feng Li; An-Ming Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-02-12

2.  6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.

Authors:  Benjamin J Buckley; Ashraf Aboelela; Elahe Minaei; Longguang X Jiang; Zhihong Xu; Umar Ali; Karen Fildes; Chen-Yi Cheung; Simon M Cook; Darren C Johnson; Daniel A Bachovchin; Gregory M Cook; Minoti Apte; Mingdong Huang; Marie Ranson; Michael J Kelso
Journal:  J Med Chem       Date:  2018-09-07       Impact factor: 7.446

3.  Improved pharmacokinetic and biodistribution properties of the selective urokinase inhibitor PAI-2 (SerpinB2) by site-specific PEGylation: implications for drug delivery.

Authors:  Kara Lea Vine; Sergei Lobov; Vineesh Indira Chandran; Nathanial Lachlan Ewart Harris; Marie Ranson
Journal:  Pharm Res       Date:  2014-09-18       Impact factor: 4.200

4.  Reduced monocyte adhesion to aortae of diabetic plasminogen activator inhibitor-1 knockout mice.

Authors:  Ruozhi Zhao; Khuong Le; Mohammed H Moghadasian; Garry X Shen
Journal:  Inflamm Res       Date:  2017-05-26       Impact factor: 4.575

5.  Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor.

Authors:  Henrik Gårdsvoll; Magnus Kjaergaard; Benedikte Jacobsen; Mette C Kriegbaum; Mingdong Huang; Michael Ploug
Journal:  J Biol Chem       Date:  2011-10-24       Impact factor: 5.157

Review 6.  Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.

Authors:  Nehad S El Salamouni; Benjamin J Buckley; Marie Ranson; Michael J Kelso; Haibo Yu
Journal:  Biophys Rev       Date:  2022-01-06

Review 7.  Impact of proteolytic enzymes in colorectal cancer development and progression.

Authors:  László Herszényi; Loránd Barabás; István Hritz; Gábor István; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

8.  A novel tumor targeting drug carrier for optical imaging and therapy.

Authors:  Rui Li; Ke Zheng; Ping Hu; Zhuo Chen; Shanyong Zhou; Jincan Chen; Cai Yuan; Song Chen; Wei Zheng; En Ma; Fengling Zhang; Jinping Xue; Xueyuan Chen; Mingdong Huang
Journal:  Theranostics       Date:  2014-03-24       Impact factor: 11.556

Review 9.  Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials.

Authors:  Rui Li; Ke Zheng; Cai Yuan; Zhuo Chen; Mingdong Huang
Journal:  Nanotheranostics       Date:  2017-07-11

10.  Methionine deprivation suppresses triple-negative breast cancer metastasis in vitro and in vivo.

Authors:  Hyein Jeon; Jae Hwan Kim; Eunjung Lee; Young Jin Jang; Joe Eun Son; Jung Yeon Kwon; Tae-Gyu Lim; Sunghoon Kim; Jung Han Yoon Park; Jong-Eun Kim; Ki Won Lee
Journal:  Oncotarget       Date:  2016-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.